Table 1.
Characteristics of treatment-naïve chronic hepatitis C patients with genotype 2 and low viral load at the start of treatment (mean ± SD)
| 4-wk treatment group (n = 22) | 12-wk treatment group (n = 11) | |
| Gender (M/F) | 10/12 | 6/5 |
| Age (yr) | 57 ± 10 | 56 ± 12 |
| Body weight (kg) | 58.5 ± 10.7 | 60.6 ± 10.4 |
| Body mass index (kg/m2) | 23.0 ± 2.9 | 21.8 ± 2.2 |
| History of transfusion (yes/no) | 10/12 | 3/8 |
| Initial dosage (180 μg/90 μg) | 20/2 | 9/2 |
| Aspartate transaminase (IU/L) | 53 ± 27 | 55 ± 32 |
| Alanine transaminase (IU/L) | 75 ± 35 | 77 ± 36 |
| γ-glutamyl transpeptidase (IU/L) | 52 ± 24 | 48 ± 30 |
| Albumin (g/dL) | 4.3 ± 0.3 | 4.2 ± 0.3 |
| Total cholesterol (mg/dL) | 169 ± 22 | 182 ± 35 |
| Platelet count (× 103/μL) | 157 ± 58 | 165 ± 62 |
| Hemoglobin (g/dL) | 13.3 ± 1.6 | 13.6 ± 1.8 |
| Leukocyte count (/μL) | 4700 ± 1500 | 5300 ± 900 |
| Neutrophil count (/μL) | 2490 ± 1140 | 2550 ± 613 |
| Liver histology | ||
| Stage (1/2/3/4) | 9/5/5/0 | 5/4/2/0 |
| Grade (mild/moderate/severe) | 11/8/0 | 8/3/0 |
| Steatosis (mild/moderate/severe) | 15/4/0 | 9/2/0 |
| Viral load (KIU/mL) | 24 ± 21 | 24 ± 22 |